Tradestie Institutional Equity Comparison Engine

XOMA vs DMAC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DMAC Overall Edge

DMAC Captures Institutional Edge (3โ€“1 Pillars ยท 2โ€“8 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while XOMA counters with relative strength in Valuation. Fundamentally, XOMA trades at 21.5x Forward P/E with -3.9% operating margin (-22.6% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, XOMA sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner XOMA
XOMA 21.5x vs DMAC N/M Fwd P/E
Growth & Margin Winner DMAC
Op Margin -3.9% vs 0.0% ยท YoY -22.6% vs +0.0%
Momentum & Technical Winner DMAC
1Y +44.0% vs +55.3% ยท 52W Pos 78% vs 55%
Options & Structure Winner DMAC
UNCLASSIFIED (100th %ile IV) vs SURGE (14th %ile IV)
XOMA NASDAQ
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
1M Return -3.81%
1Y Return +43.98%
Forward P/E 21.5x
Unified AI Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
1M Return +11.16%
1Y Return +55.26%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: XOMA +43.98% DMAC +55.26% Spread: +13.59 pp (DMAC Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
XOMA TTM Op. Margin: -3.9% DMAC TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs DMAC. Trailing 12-month operating profitability (XOMA -3.9% vs DMAC 0.0%) and valuation multiples (XOMA 21.5x vs DMAC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: XOMA (8) vs DMAC (2)
Institutional Metric XOMA DMAC Criterion Row Winner
Market Capitalization Scale $781.8M $503.1M Larger Scale XOMA
Trailing P/E Ratio Valuation 28.2x N/M Lower Multiple XOMA
Forward P/E Ratio Valuation 21.5x N/M Lower Multiple XOMA
Revenue Growth (YoY) Growth -22.6% +0.0% Higher Growth DMAC
Operating Margin (TTM) Profitability -3.9% 0.0% Higher Margin DMAC
Net Profit Margin Profitability 69.6% 0.0% Higher Margin XOMA
Return on Equity (ROE) Capital Efficiency 34.2% -114.6% Higher ROE XOMA
52-Week Range Position Momentum 78% ($22โ€“$45) 55% ($5โ€“$11) Stronger Trend XOMA
Beta / 30D Volatility Risk Regime 0.68ฮฒ ยท 37% Vol 1.74ฮฒ ยท 98% Vol Lower Realized Risk XOMA
Unified Institutional Score Composite Signal 55.8 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite XOMA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full XOMA vs DMAC Buy Guide
XOMA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live XOMA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live DMAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither XOMA nor DMAC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.